cross-sectional area of vehicle-or GLP-2-treated control and IE-igf1rKO mice. Control and knockou... more cross-sectional area of vehicle-or GLP-2-treated control and IE-igf1rKO mice. Control and knockout mice also demonstrated an increase in small intestinal weight with GLP-2 treatment (p<0.05 for control and p<0.01 for IE-igf1rKO animals), as compared to vehicle-treated animals. However, IE-igf1rKO mice exhibited a marked decrease in GLP-2-induced cryptvillus height (p<0.05) and in the number of Ki67+-proliferating cells (p<0.05) following GLP-2 treatment, relative to controls. These findings demonstrate that selective expression of the IGF-1 receptor in the intestinal epithelium is essential for the proliferative effects of chronic GLP-2 administration.
cross-sectional area of vehicle-or GLP-2-treated control and IE-igf1rKO mice. Control and knockou... more cross-sectional area of vehicle-or GLP-2-treated control and IE-igf1rKO mice. Control and knockout mice also demonstrated an increase in small intestinal weight with GLP-2 treatment (p<0.05 for control and p<0.01 for IE-igf1rKO animals), as compared to vehicle-treated animals. However, IE-igf1rKO mice exhibited a marked decrease in GLP-2-induced cryptvillus height (p<0.05) and in the number of Ki67+-proliferating cells (p<0.05) following GLP-2 treatment, relative to controls. These findings demonstrate that selective expression of the IGF-1 receptor in the intestinal epithelium is essential for the proliferative effects of chronic GLP-2 administration.
Uploads
Papers by Daniela Ibarra